A Single-Centre, Open-Label, Sequential, Dose-Ascending Study to Examine Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Intravenous, Inhaled and Oral Doses of GW642444 [GSK-642444] in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Vilanterol (Primary) ; Vilanterol (Primary) ; Vilanterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 29 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2008 Planned end date changed from 1 Aug 2008 to 1 Dec 2008.